Skip to main content
Notice of the 2025 Annual General Meeting Published
August 4, 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
July 30, 2025
Medincell Proposes Board Appointments of Dr. Sharon Mates and Dr. Charles Kunsch
July 29, 2025
Press Release: Consolidated Annual Financial Results
June 17, 2025
Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation
May 28, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
May 7, 2025
Medincell and iM4TB Join Forces to Fight Tuberculosis
April 22, 2025
Increase in the Amount Allocated to the Liquidity Contract
April 15, 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
March 31, 2025
Medincell Strengthens its Board of Directors
March 6, 2025
